Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

被引:344
|
作者
Levine-Tiefenbrun, Matan [1 ]
Yelin, Idan [1 ]
Katz, Rachel [2 ]
Herzel, Esma [2 ]
Golan, Ziv [3 ]
Schreiber, Licita [3 ]
Wolf, Tamar [3 ]
Nadler, Varda [3 ]
Ben-Tov, Amir [2 ,4 ]
Kuint, Jacob [2 ,4 ]
Gazit, Sivan [2 ]
Patalon, Tal [2 ]
Chodick, Gabriel [2 ,4 ]
Kishony, Roy [1 ,5 ]
机构
[1] Technion Israel Inst Technol, Fac Biol, Haifa, Israel
[2] Maccabitech, Maccabi Hlth Serv, Tel Aviv, Israel
[3] Maccabi Healthcare Serv, Maccabi Mega Lab, Rehovot, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Technion Israel Inst Technol, Fac Comp Sci, Haifa, Israel
基金
以色列科学基金会;
关键词
D O I
10.1038/s41591-021-01316-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Beyond their substantial protection of individual vaccinees, coronavirus disease 2019 (COVID-19) vaccines might reduce viral load in breakthrough infection and thereby further suppress onward transmission. In this analysis of a real-world dataset of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results after inoculation with the BNT162b2 messenger RNA vaccine, we found that the viral load was substantially reduced for infections occurring 12-37 d after the first dose of vaccine. These reduced viral loads hint at a potentially lower infectiousness, further contributing to vaccine effect on virus spread. Breakthrough infections of SARS-CoV-2 occurring 12 or more days after the first dose of the BNT162b2 mRNA vaccine were associated with lower viral loads than those found in unvaccinated individuals, suggesting that the vaccine might reduce infectiousness.
引用
收藏
页码:790 / +
页数:13
相关论文
共 50 条
  • [21] Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
    Psichogiou, Mina
    Karabinis, Andreas
    Poulakou, Garyphallia
    Antoniadou, Anastasia
    Kotanidou, Anastasia
    Degiannis, Dimitrios
    Pavlopoulou, Ioanna D.
    Chaidaroglou, Antigoni
    Roussos, Sotirios
    Mastrogianni, Elpida
    Eliadi, Irene
    Basoulis, Dimitrios
    Petsios, Konstantinos
    Leontis, Konstantinos
    Kakalou, Eleni
    Protopapas, Konstantinos
    Jahaj, Edison
    Pratikaki, Maria
    Syrigos, Konstantinos N.
    Lagiou, Pagona
    Gogas, Helen
    Tsiodras, Sotirios
    Magiorkinis, Gkikas
    Paraskevis, Dimitrios
    Sypsa, Vana
    Hatzakis, Angelos
    VACCINES, 2021, 9 (09)
  • [22] Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine
    Pellini, Raul
    Venuti, Aldo
    Pimpinelli, Fulvia
    Abril, Elva
    Blandino, Giovanni
    Campo, Flaminia
    Conti, Laura
    De Virgilio, Armando
    De Marco, Federico
    Di Domenico, Enea Gino
    Di Bella, Ornella
    Di Martino, Simona
    Ensoli, Fabrizio
    Giannarelli, Diana
    Mandoj, Chiara
    Manciocco, Valentina
    Marchesi, Paolo
    Mazzola, Francesco
    Moretto, Silvia
    Petruzzi, Gerardo
    Petrone, Fabrizio
    Pichi, Barbara
    Pontone, Martina
    Zocchi, Jacopo
    Vidiri, Antonello
    Vujovic, Branka
    Piaggio, Giulia
    Morrone, Aldo
    Ciliberto, Gennaro
    ECLINICALMEDICINE, 2021, 36
  • [23] Myocarditis after BNT162b2 mRNA SARS-CoV-2 vaccine: low incidence and mild severity
    Liuzzo, Giovanna
    Volpe, Massimo
    EUROPEAN HEART JOURNAL, 2022, 43 (09) : 855 - 856
  • [24] A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine
    Mira, Filipe S.
    Carvalho, Joni Costa
    de Almeida, Patricia Amaral
    Pimenta, Ana Carolina
    Coutinho, Iolanda Alen
    Figueiredo, Carolina
    Rodrigues, Luis
    Sousa, Vitor
    Ferreira, Emanuel
    Pinto, Helena
    Escada, Luis
    Galvao, Ana
    Alves, Rui
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2021, 14 : 421 - 426
  • [25] Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients
    Valleriani, Fabrizia
    Mancuso, Elisa
    Vincifori, Giacomo
    Teodori, Liana
    Di Marcantonio, Lisa
    Spedicato, Massimo
    Leone, Alessandra
    Savini, Giovanni
    Morelli, Daniela
    Bonfini, Barbara
    Lorusso, Alessio
    VIRUSES-BASEL, 2021, 13 (10):
  • [26] Effectiveness of BNT162b2 vaccine against SARS-CoV-2 among healthcare workers
    Sansone, Emanuele
    Sala, Emma
    Tiraboschi, Mara
    Albini, Elisa
    Lombardo, Massimo
    Indelicato, Annamaria
    Rosati, Cristina
    Boniotti, Maria Beatrice
    Castelli, Francesco
    De Palma, Giuseppe
    MEDICINA DEL LAVORO, 2021, 112 (03): : 250 - 255
  • [27] Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
    Chemaitelly, Hiam
    Tang, Patrick
    Hasan, Mohammad R.
    AlMukdad, Sawsan
    Yassine, Hadi M.
    Benslimane, Fatiha M.
    Al Khatib, Hebah A.
    Coyle, Peter
    Ayoub, Houssein H.
    Al Kanaani, Zaina
    Al Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar H.
    Latif, Ali N.
    Shaik, Riyazuddin M.
    Rahim, Hanan F. Abdul
    Nasrallah, Gheyath K.
    Al Kuwari, Mohamed G.
    Al Romaihi, Hamad E.
    Butt, Adeel A.
    Al-Thani, Mohamed H.
    Al Khal, Abdullatif
    Bertollini, Roberto
    Abu-Raddad, Laith J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24): : E83 - E83
  • [28] Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster
    Salvagno, G. L.
    Henry, B. M.
    Lippi, G.
    INFECTIOUS DISEASES NOW, 2022, 52 (06): : 379 - 380
  • [29] Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV
    Touizer, Emma
    Alrubayyi, Aljawharah
    Rees-Spear, Chloe
    Fisher-Pearson, Natasha
    Griffith, Sarah
    Muir, Luke
    Pellegrino, Pierre
    Waters, Laura
    Burns, Fiona
    Kinloch, Sabine
    Rowland-Jones, Sarah
    Gupta, Ravindra
    Gilson, Richard
    Peppa, Dimitra
    McCoy, Laura
    LANCET HIV, 2021, 8 (06): : E317 - E318
  • [30] Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer
    Debie, Yana
    Vandamme, Timon
    Goossens, Maria E.
    van Dam, Peter A.
    Peeters, Marc
    EUROPEAN JOURNAL OF CANCER, 2022, 163 : 177 - 179